No retraction, correction or concern found when last checked on Oct 29, 2026.

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas and 97 more

The Lancet · 2021 · Randomised trial · CC BY

doi:10.1101/2021.02.11.21249258

Abstract

Background. In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.

Methods. This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936).

Findings. Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001).

Interpretation. In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids.

Funding. UK Research and Innovation (Medical Research Council) and National Institute of Health Research.

References 30

1.
Estimates of the severity of coronavirus disease 2019: a model-based analysis · 2020
Corrected
2.
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study · 2020
No notice
3.
Chen N, Zhou M, Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513.
Not in our library10.1016/s0140-6736(20)30211-7
4.
Del Valle DM, Kim-Schulze S, Huang HH. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636-1643.
Not in our library10.1038/s41591-020-1051-9
5.
Tissue-Specific Immunopathology in Fatal COVID-19 · 2021
No notice
6.
RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693-704.
Not in our library10.1056/nejmoa2021436
7.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: meta-analysis A. JAMA. 2020;324:1330-1341.
Not in our library10.1001/jama.2020.17023
8.
Veiga VC, Prats JAGG, Farias DLC. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:n84.
Not in our library10.1136/bmj.n84
9.
Rosas I, Bräu N, Waters M. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv. 2020.
Not in our library10.1101/2020.08.27.20183442
10.
Hermine O, Mariette X, Tharaux PL. Effect of tocilizumab vs usual care in adults hospitalized with covid-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:32-40.
Not in our library10.1001/jamainternmed.2020.6820
11.
Salvarani C, Dolci G, Massari M. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with covid-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:24-31.
Not in our library10.1001/jamainternmed.2020.6615
12.
Stone JH, Frigault MJ, Serling-Boyd NJ. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383:2333-2344.
Not in our library10.1056/nejmoa2028836
13.
Salama C, Han J, Yau L. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384:20-30.
Not in our library10.1056/nejmoa2030340
14.
Soin AS, Kumar K, Choudhary NS. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021.
Not in our library10.1016/s2213-2600(21)00081-3
15.
Gordon AC, Mouncey PR, Al-Beidh F. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19—preliminary report. medRxiv. 2021.
Not in our library10.1056/nejmoa2100433
16.
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 · 2020
No notice
17.
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial · 2021
No notice
18.
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial · 2020
No notice
19.
Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer: worldwide evidence 1985–1990. 1990.
Not in our library
20.
Baskaran V, Lawrence H, Lansbury L. Co-infection in critically ill patients with COVID-19: an observational cohort study from England. medRxiv. 2020.
Not in our library10.1101/2020.10.27.20219097
21.
Lescure FX, Honda H, Fowler RA. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021.
Not in our library10.1016/s2213-2600(21)00099-0
22.
Murthy S, Lee TC. IL-6 blockade for COVID-19: a global scientific call to arms. Lancet Respir Med. 2021.
Not in our library10.1016/s2213-2600(21)00127-2
23.
Escadafal C, Incardona S, Fernandez-Carballo BL, Dittrich S. The good and the bad: using C reactive protein to distinguish bacterial from non-bacterial infection among febrile patients in low-resource settings. BMJ Glob Health. 2020;5.
Not in our library10.1136/bmjgh-2020-002396
24.
Oberhoffer M, Karzai W, Meier-Hellmann A, Bögel D, Fassbinder J, Reinhart K. Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis. Crit Care Med. 1999;27:1814-1818.
Not in our library10.1097/00003246-199909000-00018
25.
Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
Not in our library10.1056/nejmoa2002032
26.
Qin C, Zhou L, Hu Z. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762-768.
Not in our library10.1093/cid/ciaa248
27.
Wang L, He W, Yu X. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020;80:639-645.
Not in our library10.1016/j.jinf.2020.03.019
28.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846-848.
Not in our library10.1007/s00134-020-05991-x
29.
Department of Health and Social Care. Interleukin-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 pneumonia (adults). 2021.
Not in our library
30.
National Institutes of Health. The COVID-19 treatment guidelines panel's statement on the use of tocilizumab for the treatment of COVID-19. 2021.
Not in our library

Cited by papers we hold 26

Deep insight into cytokine storm: from pathogenesis to treatment · 2025
No notice
Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response · 2023
Not checked
Using genetic association data to guide drug discovery and development: Review of methods and applications · 2023
No notice
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease · 2023
No notice
Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A Mendelian randomisation study · 2023
No notice
Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study · 2022
Not checked
Investigation of target sequencing of SARS-CoV-2 and immunogenic GWAS profiling in host cells of COVID-19 in Vietnam · 2022
Not checked
Potent Anti‐SARS‐CoV‐2 Efficacy of COVID‐19 Hyperimmune Globulin from Vaccine‐Immunized Plasma · 2022
Not checked
Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19 · 2022
Not checked
Myeloid-Derived Suppressor Cells in COVID-19: The Paradox of Good · 2022
Not checked
Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19—Results From a Pilot Open-Label, Randomized Controlled Trial · 2022
Not checked
Outcomes associated with tocilizumab with or without corticosteroid versus dexamethasone for treatment of patients with severe to critical COVID-19 pneumonia · 2022
Not checked
COVID-19 therapeutics: Challenges and directions for the future · 2022
No notice
Cytokine Storm in COVID-19: Immunopathogenesis and Therapy · 2022
No notice
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection · 2022
No notice
A Bittersweet Response to Infection in Diabetes; Targeting Neutrophils to Modify Inflammation and Improve Host Immunity · 2021
No notice
Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial · 2021
Not checked
A systematic review on the effects of Echinacea supplementation on cytokine levels: Is there a role in COVID-19? · 2021
Not checked
Altered Cytokine Endotoxin Responses in Neonatal Encephalopathy Predict MRI Outcomes · 2021
Not checked
Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19 · 2021
Not checked

and 6 more

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.